Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
35
SKYE Quote, Financials, Valuation and Earnings
Last price:
$0.78
Seasonality move
:
25.44%
Day range:
$0.74 - $0.82
52-week range:
$0.68 - $5.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
476.49x
P/B ratio:
0.76x
Volume:
130.8K
Avg. volume:
324.3K
1-year change:
-75.47%
Market cap:
$25M
Revenue:
--
EPS (TTM):
-$1.29
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SKYE
Skye Bioscience, Inc.
|
-- | -$0.31 | -- | -22.14% | $8.25 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835.1M | $0.59 | 11.8% | 33.07% | $88.87 |
|
HALO
Halozyme Therapeutics, Inc.
|
$446.1M | $2.20 | 35.44% | 85.52% | $84.50 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SKYE
Skye Bioscience, Inc.
|
$0.78 | $8.25 | $25M | -- | $0.00 | 0% | 476.49x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$24.33 | $31.21 | $4.1B | 15.65x | $0.00 | 0% | 3.91x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$339.37 | $457.00 | $45B | 150.36x | $0.00 | 0% | 12.20x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$63.42 | $88.87 | $12.2B | 23.76x | $0.00 | 0% | 4.02x |
|
HALO
Halozyme Therapeutics, Inc.
|
$72.04 | $84.50 | $8.5B | 28.91x | $0.00 | 0% | 6.33x |
|
SVRA
Savara, Inc.
|
$5.72 | $10.81 | $1.2B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SKYE
Skye Bioscience, Inc.
|
0.97% | 6.090 | 0.26% | 4.22x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.896 | 5.87% | 2.84x |
|
HALO
Halozyme Therapeutics, Inc.
|
97.81% | -1.035 | 27.51% | 3.35x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SKYE
Skye Bioscience, Inc.
|
-$178.9K | -$13.3M | -91.01% | -91.57% | -- | -$13.4M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
HALO
Halozyme Therapeutics, Inc.
|
$349.6M | $254.4M | 15.89% | 91.5% | 56.31% | $217.6M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
Skye Bioscience, Inc. vs. Competitors
-
Which has Higher Returns SKYE or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Skye Bioscience, Inc.'s net margin of 25.76%. Skye Bioscience, Inc.'s return on equity of -91.57% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital SKYESkye Bioscience, Inc.-- -$0.32 $33.2M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About SKYE or ACAD?
Skye Bioscience, Inc. has a consensus price target of $8.25, signalling upside risk potential of 957.42%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 28.28%. Given that Skye Bioscience, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Skye Bioscience, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SKYESkye Bioscience, Inc.4 2 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is SKYE or ACAD More Risky?
Skye Bioscience, Inc. has a beta of 2.869, which suggesting that the stock is 186.859% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock SKYE or ACAD?
Skye Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Skye Bioscience, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SKYE or ACAD?
Skye Bioscience, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Skye Bioscience, Inc.'s net income of -$12.8M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Skye Bioscience, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Skye Bioscience, Inc. is 476.49x versus 3.91x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SKYESkye Bioscience, Inc.476.49x -- -- -$12.8M ACADACADIA Pharmaceuticals, Inc.3.91x 15.65x $278.6M $71.8M
-
Which has Higher Returns SKYE or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Skye Bioscience, Inc.'s net margin of 16.99%. Skye Bioscience, Inc.'s return on equity of -91.57% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital SKYESkye Bioscience, Inc.-- -$0.32 $33.2M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About SKYE or ALNY?
Skye Bioscience, Inc. has a consensus price target of $8.25, signalling upside risk potential of 957.42%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 34.66%. Given that Skye Bioscience, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Skye Bioscience, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SKYESkye Bioscience, Inc.4 2 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is SKYE or ALNY More Risky?
Skye Bioscience, Inc. has a beta of 2.869, which suggesting that the stock is 186.859% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock SKYE or ALNY?
Skye Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Skye Bioscience, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SKYE or ALNY?
Skye Bioscience, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Skye Bioscience, Inc.'s net income of -$12.8M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Skye Bioscience, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 150.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Skye Bioscience, Inc. is 476.49x versus 12.20x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SKYESkye Bioscience, Inc.476.49x -- -- -$12.8M ALNYAlnylam Pharmaceuticals, Inc.12.20x 150.36x $1.1B $186.4M
-
Which has Higher Returns SKYE or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -- compared to Skye Bioscience, Inc.'s net margin of -3.91%. Skye Bioscience, Inc.'s return on equity of -91.57% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital SKYESkye Bioscience, Inc.-- -$0.32 $33.2M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About SKYE or BMRN?
Skye Bioscience, Inc. has a consensus price target of $8.25, signalling upside risk potential of 957.42%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 40.13%. Given that Skye Bioscience, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Skye Bioscience, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SKYESkye Bioscience, Inc.4 2 0 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is SKYE or BMRN More Risky?
Skye Bioscience, Inc. has a beta of 2.869, which suggesting that the stock is 186.859% more volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock SKYE or BMRN?
Skye Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Skye Bioscience, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SKYE or BMRN?
Skye Bioscience, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Skye Bioscience, Inc.'s net income of -$12.8M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Skye Bioscience, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 23.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Skye Bioscience, Inc. is 476.49x versus 4.02x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SKYESkye Bioscience, Inc.476.49x -- -- -$12.8M BMRNBioMarin Pharmaceutical, Inc.4.02x 23.76x $786.8M -$30.7M
-
Which has Higher Returns SKYE or HALO?
Halozyme Therapeutics, Inc. has a net margin of -- compared to Skye Bioscience, Inc.'s net margin of -31.34%. Skye Bioscience, Inc.'s return on equity of -91.57% beat Halozyme Therapeutics, Inc.'s return on equity of 91.5%.
Company Gross Margin Earnings Per Share Invested Capital SKYESkye Bioscience, Inc.-- -$0.32 $33.2M HALOHalozyme Therapeutics, Inc.77.39% -$1.20 $2.2B -
What do Analysts Say About SKYE or HALO?
Skye Bioscience, Inc. has a consensus price target of $8.25, signalling upside risk potential of 957.42%. On the other hand Halozyme Therapeutics, Inc. has an analysts' consensus of $84.50 which suggests that it could grow by 17.3%. Given that Skye Bioscience, Inc. has higher upside potential than Halozyme Therapeutics, Inc., analysts believe Skye Bioscience, Inc. is more attractive than Halozyme Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SKYESkye Bioscience, Inc.4 2 0 HALOHalozyme Therapeutics, Inc.4 2 1 -
Is SKYE or HALO More Risky?
Skye Bioscience, Inc. has a beta of 2.869, which suggesting that the stock is 186.859% more volatile than S&P 500. In comparison Halozyme Therapeutics, Inc. has a beta of 0.968, suggesting its less volatile than the S&P 500 by 3.227%.
-
Which is a Better Dividend Stock SKYE or HALO?
Skye Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Halozyme Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Skye Bioscience, Inc. pays -- of its earnings as a dividend. Halozyme Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SKYE or HALO?
Skye Bioscience, Inc. quarterly revenues are --, which are smaller than Halozyme Therapeutics, Inc. quarterly revenues of $451.8M. Skye Bioscience, Inc.'s net income of -$12.8M is higher than Halozyme Therapeutics, Inc.'s net income of -$141.6M. Notably, Skye Bioscience, Inc.'s price-to-earnings ratio is -- while Halozyme Therapeutics, Inc.'s PE ratio is 28.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Skye Bioscience, Inc. is 476.49x versus 6.33x for Halozyme Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SKYESkye Bioscience, Inc.476.49x -- -- -$12.8M HALOHalozyme Therapeutics, Inc.6.33x 28.91x $451.8M -$141.6M
-
Which has Higher Returns SKYE or SVRA?
Savara, Inc. has a net margin of -- compared to Skye Bioscience, Inc.'s net margin of --. Skye Bioscience, Inc.'s return on equity of -91.57% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital SKYESkye Bioscience, Inc.-- -$0.32 $33.2M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About SKYE or SVRA?
Skye Bioscience, Inc. has a consensus price target of $8.25, signalling upside risk potential of 957.42%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 89.03%. Given that Skye Bioscience, Inc. has higher upside potential than Savara, Inc., analysts believe Skye Bioscience, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SKYESkye Bioscience, Inc.4 2 0 SVRASavara, Inc.6 0 0 -
Is SKYE or SVRA More Risky?
Skye Bioscience, Inc. has a beta of 2.869, which suggesting that the stock is 186.859% more volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock SKYE or SVRA?
Skye Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Skye Bioscience, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SKYE or SVRA?
Skye Bioscience, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Skye Bioscience, Inc.'s net income of -$12.8M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Skye Bioscience, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Skye Bioscience, Inc. is 476.49x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SKYESkye Bioscience, Inc.476.49x -- -- -$12.8M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 0.82% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 0.05% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 0.54% over the past day.
